Skip to content
Editorial standardsAdvertise
MeridiansIndependent reporting, reviews and buying advice
LIVE
Health/

One Lot of Thyroid Medication Recalled for Being Too Strong

Vitruvias Therapeutics pulled a single lot of 30 mg thyroid tablets after testing found they could be "superpotent." No adverse events have been reported, and the FDA says not to stop taking the medication without talking to your doctor first.

Meridians Life Desk

Published 27 August 2026 · Updated 27 August 2026 · 4 min read

One Lot of Thyroid Medication Recalled for Being Too StrongHealth
Photo: Photo by Etatics Inc. / Pexels (Pexels License — free to use, no attribution legally required (credited above as good practice).)

The short answer

  • Vitruvias Therapeutics, Inc. recalled one lot of Thyroid Tablets, USP 30 mg — lot 504950, NDC 69680-166-00 — after testing confirmed the tablets could be superpotent.
  • The lot was distributed nationwide between January 31 and September 30, 2025. About 3,655 units were released and 1,955 were sold before the recall.
  • No adverse events tied to the recall had been reported as of the FDA's late-August 2026 announcement.
  • Excess thyroid hormone can cause hyperthyroidism symptoms, including rapid heart rate and heat intolerance; the FDA flags elderly patients, pregnant women and infants as facing the greatest risk.

Vitruvias Therapeutics, Inc., of Auburn, Alabama, is recalling one lot of Thyroid Tablets, USP 30 mg after testing confirmed the tablets have the potential to be superpotent — meaning they may contain more active thyroid hormone than the label states. The recall, posted by the FDA on August 24, 2026, has not been linked to any confirmed adverse events.

What's affected

  • Product: Thyroid Tablets, USP 30 mg
  • Lot number: 504950
  • NDC: 69680-166-00
  • Expiration date: September 30, 2026
  • Distributed nationwide January 31 – September 30, 2025
  • About 3,655 units released; 1,955 sold

Why potency, not contamination, is the concern

Thyroid hormone replacement drugs work in a narrow range: too little and hypothyroidism symptoms persist, too much can push the body toward hyperthyroidism. The FDA lists weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate and heart rhythm disturbances as possible effects of taking a superpotent tablet, with elderly patients, pregnant women and infants at elevated risk, particularly with extended use.

What to do

  • Check your bottle for lot number 504950 and NDC 69680-166-00.
  • Do not stop taking the medication on your own — thyroid hormone withdrawal carries its own risks.
  • Contact your pharmacist or prescriber for a replacement prescription if your bottle matches.
  • Report problems to Vitruvias at safety@vitruvias.com or 256-239-9373, or to FDA MedWatch.

Sources

Every factual claim above is traceable to these documents. Check them — that is why they are here.

About this byline

Meridians Life Desk is an editorial desk at Meridians, not an individual. A desk byline means the article was produced and fact-checked to that desk's published standards. Read our editorial standards and corrections policy.

Sponsored

Paid placement · not editorial

Related reading

The Meridians Brief

One considered email a week

What changed, what it costs you, and what to do about it — from the Meridians desks. No sponsored picks disguised as recommendations.

Sign-up opens with our launch issue. Nothing is sent or stored yet.